Lantern Pharma Will Raise $4M Through Share Offering
The Dallas-based firm will issue over 3.6 million shares to bolster working capital for general corporate purposes.
Updated on Sept. 29, 2026 in Corporate Finance
Live Poll
Do you trust the long-term potential of small, AI-driven biopharmaceutical companies?
Lantern Pharma will execute a registered direct offering of 3,669,725 shares at $1.09 per share on or about September 30, 2026. The transaction is expected to generate approximately $4 million in gross proceeds for the company.
Why it matters
The capital raise provides the company with immediate liquidity to support its ongoing operations and general business requirements. This influx of working capital allows the firm to maintain its strategic trajectory without relying on debt financing or traditional bank facilities.
The company is selling 3,669,725 shares at $1.09 each, targeting $4 million in immediate gross proceeds. The deal also includes unregistered warrants for an additional 3,669,725 shares, which could generate a further $4 million upon exercise.
The players
Lantern Pharma
A Dallas-based biopharmaceutical company that leverages AI and machine learning to accelerate the development of precision oncology therapeutics.
Rodman & Renshaw LLC
An investment bank and brokerage firm that acts as a placement agent for capital market transactions.
The details
The offering is structured through a shelf registration statement on Form S-3 and includes a prospectus supplement. Rodman & Renshaw LLC is serving as the placement agent for the transaction. The warrants carry an exercise price of $1.09 per share and remain valid for five years following required stockholder approval for the issuance of the underlying shares.
Timeline
May 24, 2024: The company filed a shelf registration statement with the SEC.
June 10, 2024: The shelf registration statement became effective.
September 29, 2026: Lantern Pharma announced the definitive agreement.
September 30, 2026: The offering is expected to close.
Market Landscape
This transaction follows the established mechanism of using an effective SEC Form S-3 shelf registration to conduct a rapid capital raise. The strategy allows public companies to tap capital markets efficiently when they require liquidity for operational runway.
Operators should monitor the dilution impact on existing equity structures when evaluating similar direct offerings as a capital strategy. Reviewing the terms of warrant exercises is essential for understanding the total potential equity expansion for the firm.
The takeaway
Direct offerings allow firms to raise capital quickly, but they come with specific requirements like the upcoming stockholder vote on warrant issuance. Owners should track the dilution effects if they are considering similar equity-based fundraising models.
What happens next
Stockholders will be required to vote on the issuance of shares related to the exercise of the warrants, a key milestone for the long-term potential of the warrant capital.
Further reading
For broader trends in equity financing, see Corporate Finance.
More information
Review the full details regarding this offering on the SEC website for prospectus.
Live Poll
Do you trust the long-term potential of small, AI-driven biopharmaceutical companies?
